Long-term side effects and cosmetic outcome in a pool of breast cancer patients treated with intraoperative radiotherapy with electrons as sole treatment

Maria Cristina Leonardi1, Giovanni Battista Ivaldi2, Luigi Santoro3, Roberta Lazzari1, Annamaria Ferrari1, Anna Morra1, Pietro Caldarella4, Loredana Burgoa5, Fabio Domenico Bassi4, Claudia Sangalli4, Nicole Rotmensz1, Alberto Luini4, Umberto Veronesi6, and Roberto Orecchia1,7

1Division of Radiation Oncology, European Institute of Oncology, Milan; 2Radiotherapy Department, Fondazione Salvatore Maugeri, Pavia; 3Division of Epidemiology and Biostatistics, and 4Division of Breast Surgery, European Institute of Oncology, Milan; 5Division of Surgery and Senology, General Hospital, Bergamo; 6Scientific Directorate, European Institute of Oncology, Milan; 7University of Milan, Milan, Italy

ABSTRACT

Aims. To evaluate late toxicity and cosmetic outcome after intraoperative radiotherapy using electrons (ELIOT) as sole treatment modality in early breast cancer patients.

Methods. A total of 119 patients selected randomly among 1200 cases was analyzed. Late toxicities were documented using the LENT-SOMA scoring system, cosmesis was evaluated with the Harvard scale, and a numeric rating scale was used to assess symptoms.

Results. After a median follow-up of 71 months, grade II fibrosis was observed in 38 patients (31.9%) and grade III fibrosis in 7 patients (5.9%). Postoperative complications (12.6%) did not correlate with late toxicity. Physicians and patients scored cosmesis as excellent or good in 84% and 77.3% of the cases, respectively. Patient satisfaction was higher than 90%.

Conclusions. In the study, ELIOT gives low and acceptable long-term toxicity. A longer follow-up and a larger number of patients are needed to confirm these promising results.

Key words: intraoperative radiotherapy with electrons, late toxicity, partial breast irradiation.

Conflict of interest statement: All authors disclose that there are no actual or potential conflicts of interest.

Acknowledgments: The authors thank AIRC (Associazione Italiana Ricerca sul Cancro) for their invaluable support for the ELIOT studies. The authors thank Mrs Anne Fraser for Revision of the English.

Correspondence to: Maria Cristina Leonardi, MD, Division of Radiation Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
Tel +39-02-57489037; fax +39-02-94379227; email cristina.leonardi@ieo.it

Received July 7, 2011; accepted September 20, 2011.